Improvement of Recalcitrant Dissecting Cellulitis of the Scalp After a Trial of Upadacitinib.
dissecting cellulitis of scalp
follicular occlusion tetrad
folliculitis decalvans
hidradenitis suppurativa
jak inhibitor
upadacitinib
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
accepted:
16
01
2024
medline:
16
2
2024
pubmed:
16
2
2024
entrez:
16
2
2024
Statut:
epublish
Résumé
Dissecting cellulitis of the scalp (DCS) is a rare condition characterized by painful inflammatory nodules and abscesses on the scalp, often leading to sinus tracts and scarring alopecia. We present a case of DCS in a 26-year-old male who experienced significant clinical improvement following a short course of upadacitinib, a Janus kinase (JAK) inhibitor. The patient received multiple standard treatments such as topical antimicrobials, oral antibiotics, corticosteroids, and intralesional triamcinolone injections, with limited success. However, following the initiation of upadacitinib, the patient reported reduced pain, pustular draining, and bleeding, with significantly improved quality of life. To our knowledge, there is currently a paucity of literature documenting the use of JAK inhibitors for DCS. This case aims to highlight the potential of JAK inhibitors as a therapy for refractory DCS, a condition with limited treatment options.
Identifiants
pubmed: 38361718
doi: 10.7759/cureus.52377
pmc: PMC10868624
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e52377Informations de copyright
Copyright © 2024, Islam et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.